Form 4 for NVCT Nuvectis Pharma, Inc.
Accepted 2022-09-27 00:00:00 ET · period of report 2022-09-23 · accession 0001104659-22-103166 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-09-27 | 2022-09-23 | NVCT | Shemesh Shay | Chief Dev, Ops. Off | P - Purchase | $7.87 | +220 | 1.25M | +0.0% | +$1,731 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-23 | P | A | 220 | $7.87 | 1,245,065 | D | — | — | (F1) Includes 48,399 shares of restricted stock and 60,000 restricted stock units. |